The former NFL player and current Kannalife™ Sciences spokesman talked about the efforts to develop a cannabinoid-based treatment for CTE, a disease plaguing players in the NFL.
Kannalife™ Sciences spokesperson Nick Lowery was recently invited to the Reiter Than You radio show to discuss the latest developments regarding chronic traumatic encephalopathy (CTE) and the huge impact they could make in the National Football League.
Researchers from Boston University recently discovered a new biomarker that they believe will eventually allow testing for CTE in living patients. The neurodegenerative brain disease, thought previously to be only diagnosable after death, has been found prevalent among NFL players because of the high incidence of concussions and brain trauma. Earlier this month, renowned CTE researcher Dr. Bennet Omalu and colleagues were able to confirm the finding of CTE in a living patient.
Lowery, a former NFL player, called in to Reiter Than You and spoke with host Bill Reiter about these developments. The two discussed the inclination of many NFL advocates and fans to dismiss the severity and prevalence of CTE in the league, despite evidence indicating that players are at an extremely high risk of developing the disease.
Kannalife Sciences™ Efforts to Develop CTE Treatment
In the interview, Lowery spoke about the efforts of Kannalife™ Sciences to develop novel cannabinoid therapeutic drugs for CTE. He explained how research findings suggest that a particular cannabinoid – cannabidiol (CBD) – can serve as an “internal helmet” and protect the brain from neural damage and improve recovery. He talked about the research showing that traffic accident victims with cannabinoids in their systems were five times less likely to die from a brain injury.
Kannalife™ Sciences holds two license agreements with the National Institutes of Health (NIH) for U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” to develop a treatment for CTE using cannabinoids, including a CBD-like molecule called KLS-13019.
Lowery concluded by explaining to Reiter that the successful development of a proven treatment will make the brains of players more resilient and allow players to make their own decisions related to their health with greater predictability.
Discover more about Kannalife Sciences™ and the rest of Medical Marijuana, Inc.’s portfolio of companies through our news feed.